newsfilter
← Latest News
GlobeNewswire·

Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...